Volume 24 Issue 1
Jan.  2026
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2026  >  24(1): 45-49
ZHANG Xinyi, LI Ying, ZHAO Yue, HAN Shuqi, WANG Yixiao, YANG Bo. The application of KELIM score and CRS score in patients with advanced epithelial ovarian cancer undergoing neoadjurant chemotherapy[J]. Chinese Journal of General Practice, 2026, 24(1): 45-49. doi: 10.16766/j.cnki.issn.1674-4152.004326
Citation: ZHANG Xinyi, LI Ying, ZHAO Yue, HAN Shuqi, WANG Yixiao, YANG Bo. The application of KELIM score and CRS score in patients with advanced epithelial ovarian cancer undergoing neoadjurant chemotherapy[J]. Chinese Journal of General Practice, 2026, 24(1): 45-49. doi: 10.16766/j.cnki.issn.1674-4152.004326
shu

The application of KELIM score and CRS score in patients with advanced epithelial ovarian cancer undergoing neoadjurant chemotherapy

doi: 10.16766/j.cnki.issn.1674-4152.004326
  • 1.

    Department of Gynecological Oncology, the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, China

Funds:

 AHWJ2023A20297

  • Received Date: 2025-01-28
    Available Online: 2026-04-01
    Abstract
  •   Objective  To explore the prognostic value of the CA-125 elimination rate constant K (KELIM) and the chemotherapy response score (CRS) in patients with advanced epithelial ovarian cancer (AEOC), and to investigate the correlation between KELIM score, CRS score, and breast cancer susceptibility gene (BRCA) status.  Methods  Clinical data, including BRCA gene status, KELIM score, CRS score, and follow-up outcomes, were retrospectively collected from 83 patients with stage Ⅲ-Ⅳ AEOC who underwent intermediate cytoreductive surgery at the First Affiliated Hospital of Bengbu Medical University from November 2014 to May 2023. BRCA genes were classified as mutant type or wild type, KELIM was classified as ≥ 1 or < 1, CRS was classified as CRS3 or CRS1+2. Chi-square test was used to analyze the correlation between BRCA status and KELIM and CRS scores. The log-rank test and multivariate Cox regression model were used to evaluate their relationship with progression-free survival (PFS) and overall survival (OS).  Results  Among the 83 AEOC patients, 20 cases (24.1%) were in the BRCA mutant group while 63 cases (75.9%) were in the wild type group. In the BRCA mutant group, the proportions of KELIM ≥ 1 and CRS3 were higher than those in the wild type group (P < 0.05). Multivariate Cox analysis identified BRCA gene, FIGO stage, and R0 cytoreduction as independent predictors of PFS in AEOC patients (P < 0.05), while BRCA gene, CRS score, KELIM score, and R0 cytoreduction were independent predictors of OS in AEOC patients (P < 0.05).  Conclusion  Both the CRS and KELIM scores are valuable predictive indicators for the prognosis in AEOC patients. The BRCA mutation status was significantly positively correlated with both CRS3 and KELIM ≥ 1, suggesting that it can serve as a good predictor of chemotherapy response in AEOC patients.

     

    • FullText(HTML)
  • loading
    • References(15)
  • [1]
    SPILIOTIS J, IAVAZZO C, FOTIOU A, et al. Upfront or intermediate treatment of advanced ovarian cancer patients with cytoreduction plus HIPEC: results of a retrospective study[J]. J Surg Oncol, 2021, 123(2): 630-637. doi: 10.1002/jso.26280
    [2]
    陈川, 张天骄, 李敏, 等. 初次肿瘤细胞减灭术与中间性肿瘤细胞减灭术对晚期卵巢癌患者远期生存的影响真实世界临床研究[J]. 现代生物医学进展, 2023, 23(24): 4673-4677.

    CHEN C, ZHANG T J, LI M, et al. Real-world clinical study on the impact of primary tumor cell reduction and intermediate tumor cell reduction on the long-term survival of patients with advanced ovarian cancer[J]. Modern Biomedical Progress, 2023, 23(24): 4673-4677.
    [3]
    刘格格, 王丽华, 李燕华. 上皮性卵巢癌患者的BRCA1/2基因状态与其临床病理特征的相关性分析[J]. 中华全科医学, 2023, 21(5): 749-752, 768. doi: 10.16766/j.cnki.issn.1674-4152.002974

    LIU G G, WANG L H, LI Y H. Correlation analysis of BRCA1/2 gene status and its clinical pathological characteristics in patients with epithelial ovarian cancer[J]. Chinese Journal of General Practice, 2023, 21(5): 749-752, 768. doi: 10.16766/j.cnki.issn.1674-4152.002974
    [4]
    MARCHETTI C, ATASEVEN B, PERRONE A M, et al. Clinical characteristics and survival outcome of early-stage, high-grade, serous tubo-ovarian carcinoma according to BRCA mutational status[J]. Gynecol Oncol, 2024, 187: 170-177. doi: 10.1016/j.ygyno.2024.05.008
    [5]
    RODOLAKIS I, PERGIALIOTIS V, LIONTOS M, et al. Chemotherapy response score in ovarian cancer patients: an overview of its clinical utility[J]. J Clin Med, 2023, 12(6): 2155. DOI: 10.3390/jcm12062155.
    [6]
    LIONTOS M, ANDRIKOPOULOU A, KOUTSOUKOS K, et al. Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy[J]. J Ovarian Res, 2021, 14(1): 148. DOI: 10.1186/s13048-021-00902-0.
    [7]
    LI C, CUI Q L, WANG X H, et al. CA-125 elimination rate constant K (KELIM) as a promising predictor of complete cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer patients: a retrospective study from two Chinese hospitals[J]. BMC Cancer, 2024, 24(1): 609. DOI: 10.1186/s12885-024-12252-3.
    [8]
    KUS F, GUVEN D C, YILDIRIM H C, et al. KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer[J]. Biomark Med, 2023, 17(7): 379-389. doi: 10.2217/bmm-2022-0923
    [9]
    YOU B, ROBELIN P, TOD M, et al. CA-125 ELIMination rate constant K (KELIM) is a marker of chemosensitivity in patients with ovarian cancer: results from the Phase Ⅱ CHIVA trial[J]. Clin Cancer Res, 2020, 26(17): 4625-4632. doi: 10.1158/1078-0432.CCR-20-0054
    [10]
    BÖHM S, FARUQI A, SAID I, et al. Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma[J]. J Clin Oncol, 2015, 33(22): 2457-2463. doi: 10.1200/JCO.2014.60.5212
    [11]
    王少明, 郑荣寿, 韩冰峰, 等. 2022年中国人群恶性肿瘤发病与死亡年龄特征分析[J]. 中国肿瘤, 2024, 33(3): 165-174.

    WANG S M, ZHENG R S, HAN B F, et al. Analysis of the age of incidence and death of malignant tumors in the Chinese population in 2022[J]. Chinese Tumors, 2024, 33(3): 165-174.
    [12]
    倪孟冬, 吴小华. 晚期卵巢癌新辅助化疗联合间歇性肿瘤细胞减灭术[J]. 中国实用妇科与产科杂志, 2023, 39(7): 701-706.

    NI M D, WU X H. New adjuvant chemotherapy combined with intermittent tumor cell reduction for advanced ovarian cancer[J]. Chinese Journal of Practical Gynecology and Obstetrics, 2023, 39(7): 701-706.
    [13]
    程晓东, 王芬芬. 复发性卵巢癌的诊治热点[J]. 浙江医学, 2021, 43(15): 1593-1599.

    CHENG X D, WANG F F. Diagnosis and treatment of recurrent ovarian cancer[J]. Zhejiang Medicine, 2021, 43(15): 1593-1599.
    [14]
    PIGNATA S, OZA A, HALL G, et al. Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status[J]. Br J Cancer, 2025, 132(8): 725-732. doi: 10.1038/s41416-025-02966-x
    [15]
    PIEDIMONTE S, MURRAY C, ATENAFU EG, et al. Correlating the KELIM (CA125 elimination rate constant K) score and the chemo-response score as predictors of chemosensitivity in patients with advanced ovarian carcinoma[J]. Gynecol Oncol, 2024, 187: 92-97. doi: 10.1016/j.ygyno.2024.04.009
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (29) PDF downloads(1) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return